Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Quotient Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://quotient-tx.com/
Year Founded: 2021
Status: Private
BioCentury | Jan 14, 2025
Finance
How VCs at the AI-bio interface set up their portfolios for success
Some firms are playing an active role in overcoming data starvation and bolstering the infrastructure ecosystem
BioCentury | Oct 9, 2024
Product Development
How to establish causality via patient observation
Strategies to find targets in patient data are largely grounded in genetics, but the toolbox is diversifying, and increasingly longitudinal
BioCentury | Sep 4, 2024
Deals
Deals Report: Pfizer collaborates with second Flagship company, three China deals, and more
BioCentury’s weekly deals analysis
BioCentury | Aug 7, 2024
Management Tracks
Flagship’s Quotient names co-founder Campbell CSO
Plus: Cellectis hires Kilcoyne and more from Helio, Sapphiros, Pharmanovia, the ADA and Outcome Capital
BioCentury | Mar 12, 2024
Management Tracks
Hyku names Kleem Chaudhary CEO
Plus: Jones hired as CBO at MOMA, and updates from Metrion, OPPI, 4BIO and Quotient
BioCentury | Jan 6, 2024
Product Development
Flagship’s AI hub: making models that co-pioneer
The VC’s Pioneering Intelligence unit is experimenting with new methods, operationalizing tools, and creating companies
BioCentury | Nov 21, 2023
Emerging Company Profile
Quotient: discovering targets via ultra-sensitive somatic genotyping
Flagship-backed Quotient is using cutting-edge sequencing tech to identify actionable somatic mutations linked to disease states
Items per page:
1 - 7 of 7